{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:53:38Z","timestamp":1791179618425,"version":"4.1.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Recent advances in psychedelic research have renewed interest in the potential therapeutic role of psychedelic-assisted interventions in psychiatry. Early clinical trials suggest that compounds such as psilocybin and MDMA, administered within structured therapeutic frameworks, may produce rapid symptom improvements for conditions including depression, post-traumatic stress disorder, and substance use disorders. While these findings are scientifically promising, the current evidence base remains characterized by methodological and translational limitations. Many studies involve small samples, short follow-up periods, functional unblinding, and heterogeneous safety reporting, which complicate causal interpretation and generalizability. In the present paper, we examine psychedelic therapies through clinical, methodological, ethical, and implementation science lenses. We argue that current trials primarily demonstrate proof-of-concept efficacy under controlled conditions rather than readiness for large-scale clinical adoption. Responsible translation therefore requires stronger evidence regarding durability, safety monitoring, comparative effectiveness, and real-world implementation. Psychedelic therapies represent an important emerging research direction, but continued rigorous evaluation and improved implementation of established evidence-based interventions remain central to addressing mental disorders.<\/jats:p>","DOI":"10.3389\/fpsyt.2026.1922928","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:32:55Z","timestamp":1791178375000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Caution before canonisation: a clinical and implementation science perspective on psychedelics"],"prefix":"10.3389","volume":"17","author":[{"given":"Andreas","family":"Paris","sequence":"first","affiliation":[{"name":"Centre for Research in Intellectual and Developmental Disabilities, University of Warwick","place":["Coventry, United Kingdom"]},{"name":"Specialized Psychodiagnostic and Evidence-Based Consultation Services, Code Behaviour\/Modus Mores","place":["Nicosia, Cyprus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foteini","family":"Thoma","sequence":"additional","affiliation":[{"name":"Specialized Psychodiagnostic and Evidence-Based Consultation Services, Code Behaviour\/Modus Mores","place":["Nicosia, Cyprus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Velentza","sequence":"additional","affiliation":[{"name":"Specialized Psychodiagnostic and Evidence-Based Consultation Services, Code Behaviour\/Modus Mores","place":["Nicosia, Cyprus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Pavlopoulou","sequence":"additional","affiliation":[{"name":"Specialized Psychodiagnostic and Evidence-Based Consultation Services, Code Behaviour\/Modus Mores","place":["Nicosia, Cyprus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgos","family":"Metaxas","sequence":"additional","affiliation":[{"name":"Specialized Psychodiagnostic and Evidence-Based Consultation Services, Code Behaviour\/Modus Mores","place":["Nicosia, Cyprus"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1649929","article-title":"Psychedelics and mental health: Reimagining care through science, insight, and compassion","volume":"16","author":"Mikellides","year":"2025","journal-title":"Front Pharmacol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2023.2278586","article-title":"Efficacy and safety of four psychedelic-assisted therapies for adults with symptoms of depression, anxiety, and posttraumatic stress disorder: A systematic review and meta-analysis","volume":"57","author":"Bahji","year":"2025","journal-title":"J Psychoact Drugs"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078607","article-title":"Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis","volume":"386","author":"Hsu","year":"2024","journal-title":"BMJ"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q1025","article-title":"Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis","volume":"385","author":"Metaxa","year":"2024","journal-title":"BMJ"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.115886","article-title":"Efficacy and safety of psychedelics for the treatment of mental disorders: a systematic review and meta-analysis","volume":"335","author":"Yao","year":"2024","journal-title":"Psychiatry Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103517","article-title":"Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds","volume":"89","author":"Hosein","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.2546","article-title":"Adverse events in studies of classic psychedelics: A systematic review and meta-analysis","volume":"81","author":"Hinkle","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1017\/S2045796018000057","article-title":"Was Eysenck right after all? A reassessment of the effects of psychotherapy for adult depression","volume":"28","author":"Cuijpers","year":"2019","journal-title":"Epidemiol Psychiatr Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/2167702612463566","article-title":"Novel models for delivering mental health services and reducing the burdens of mental illness","volume":"1","author":"Kazdin","year":"2013","journal-title":"Clin psychol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31612-X","article-title":"The Lancet Commission on global mental health and sustainable development","volume":"392","author":"Patel","year":"2018","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.euroneuro.2023.07.011","article-title":"Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies","volume":"76","author":"Perez","year":"2023","journal-title":"Eur Neuropsychopharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12485","article-title":"MDMA-assisted psychotherapy for the treatment of PTSD: A systematic review and meta-analysis of randomized controlled trials (RCTs)","volume":"44","author":"Shahrour","year":"2024","journal-title":"Neuropsychopharmacol Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for treatment-resistant depression: A randomized clinical trial","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial","volume":"27","author":"Mitchell","year":"2023","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2026.0132","article-title":"Efficacy and safety of psilocybin in treatment-resistant major depression: The EPISODE randomized clinical trial","volume":"83","author":"Mertens","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2026.0096","article-title":"GH001 versus placebo in patients with treatment-resistant depression: A randomized clinical trial","volume":"83","author":"Cuba\u0142a","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.24119","article-title":"Control group outcomes in trials of psilocybin, SSRIs, or esketamine for depression: A meta-analysis","volume":"8","author":"Hieronymus","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11469-024-01288-y","article-title":"Navigating the \u201cPsychedelic Renaissance\u201d: From research to reality","volume":"22","author":"Payer","year":"2024","journal-title":"Int J Ment Health Addict"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaf023","article-title":"Addressing blinding in classic psychedelic studies with innovative active placebos","volume":"28","author":"Aday","year":"2025","journal-title":"Int J Neuropsychopharmacol"},{"key":"B23","unstructured":"Advancing Psychedelic Clinical Study Design\n          \n          2024"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2026.106657","article-title":"How to set up a psychedelic study: Unique considerations for research involving human participants","volume":"186","author":"Glennon","year":"2026","journal-title":"Neurosci Biobehav Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2026.0255","article-title":"Blinding integrity in psychedelic randomized clinical trials: a systematic review","volume":"83","author":"Orsini","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116677852","article-title":"Set and setting, psychedelics and the placebo response : An extra-pharmacological perspective on psychopharmacology","volume":"30","author":"Hartogsohn","year":"2016","journal-title":"J Psychopharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2025.2520221","article-title":"A scoping review of research in naturalistic studies with psychedelics","author":"Carvalho","year":"2025","journal-title":"J Psychoact Drugs"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2026.2644857","article-title":"Therapeutic-like context and relational support during psychedelic use moderate links among stress, challenging experiences, and psychological outcomes","author":"Cherniak","year":"2026","journal-title":"J Psychoact Drugs"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2026.116992","article-title":"Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland","volume":"358","author":"Aboulafia-Brakha","year":"2026","journal-title":"Psychiatry Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119897615","article-title":"Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer","volume":"34","author":"Agin-Liebes","year":"2020","journal-title":"J Psychopharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.0351","article-title":"Assessment of psilocybin therapy for patients with cancer and major depressive disorder","volume":"9","author":"Agrawal","year":"2023","journal-title":"JAMA Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20250840","article-title":"Low-dose buprenorphine following ketamine treatment for suicidal ideation in major depressive disorder: a randomized, double-blind, placebo-controlled trial","volume":"183","author":"Tucciarone","year":"2026","journal-title":"Am J Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies","volume":"25","author":"Studerus","year":"2011","journal-title":"J Psychopharmacol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2011.03.001","article-title":"Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis","volume":"27","author":"Schimmelmann","year":"2015","journal-title":"Eur Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-073725","article-title":"CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials","volume":"381","author":"Junqueira","year":"2023","journal-title":"BMJ"},{"key":"B36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1360-0443.2011.03576.x","article-title":"Ketamine use: A review","volume":"107","author":"Morgan","year":"2012","journal-title":"Addiction"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.10031.x","article-title":"Recreational ketamine: from pleasure to pain","volume":"107","author":"Wood","year":"2011","journal-title":"BJU Int"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/wps.70032","article-title":"Stanford neuromodulation therapy for treatment\u2010resistant depression: a randomized controlled trial confirming efficacy, and an EEG study providing insight into mechanism of action and a potentially predictive biomarker of efficacy","volume":"25","author":"Kratter","year":"2026","journal-title":"World Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291713000512","article-title":"Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials","volume":"44","author":"Berlim","year":"2014","journal-title":"Psychol Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.46","article-title":"Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder","volume":"67","author":"George","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"B41","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.clinph.2019.11.002","article-title":"Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation","volume":"131","author":"Lefaucheur","year":"2020","journal-title":"Clin Neurophysiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2016.04.006","article-title":"A systematic review and meta-analysis of the effects of transcranial direct current stimulation (tDCS) over the dorsolateral prefrontal cortex","volume":"9","author":"Dedoncker","year":"2016","journal-title":"Brain Stimulation"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1556\/2054.2022.00218","article-title":"Effects of psychedelics on mindfulness","volume":"6","author":"Radakovic","year":"2022","journal-title":"J Psychedelic Stud"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081723","article-title":"Psychedelic medicine: mechanisms, evidence, and translation to practice","volume":"392","author":"Jacobs","year":"2026","journal-title":"BMJ"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.917199","article-title":"Psychedelics, mystical experience, and therapeutic efficacy: A systematic review","volume":"13","author":"Ko","year":"2022","journal-title":"Front Psychiatry"},{"key":"B46","doi-asserted-by":"publisher","first-page":"24480","DOI":"10.1038\/s41598-024-74810-w","article-title":"Effects of classical psychedelics on implicit and explicit emotional empathy and cognitive empathy: a meta-analysis of MET task","volume":"14","author":"Olami","year":"2024","journal-title":"Sci Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-4-50","article-title":"Fostering implementation of health services research findings into practice: A consolidated framework","volume":"4","author":"Damschroder","year":"2009","journal-title":"Implementation Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.89.9.1322","article-title":"Evaluating the public health impact of health promotion interventions: The RE-AIM framework","volume":"89","author":"Glasgow","year":"1999","journal-title":"Am J Public Health"},{"key":"B49","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10488-010-0319-7","article-title":"Outcomes for implementation research: Conceptual distinctions, measurement challenges, and research agenda","volume":"38","author":"Proctor","year":"2011","journal-title":"Administration Policy Ment Health Ment Health Serv Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s10488-010-0327-7","article-title":"Advancing a conceptual model of evidence-based practice implementation in public service sectors","volume":"38","author":"Aarons","year":"2011","journal-title":"Administration Policy Ment Health Ment Health Serv Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2147","article-title":"The PRECIS-2 tool","volume":"350","author":"Loudon","year":"2015","journal-title":"BMJ"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103473","article-title":"United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006\u20132020","volume":"99","author":"Barnett","year":"2022","journal-title":"Int J Drug Policy"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02378-5","article-title":"Psychedelic treatments for mental health conditions pose challenges for informed consent","volume":"29","author":"Seybert","year":"2023","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2025.11.007","article-title":"Psychedelics: The pathway to implementation in the European healthcare systems","volume":"102","author":"Gr\u00fcnder","year":"2026","journal-title":"Eur Neuropsychopharmacol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2018","journal-title":"Am J Psychiatry"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2016.03.010","article-title":"The clinical TMS society consensus review and treatment recommendations for TMS therapy for major depressive disorder","volume":"9","author":"Perera","year":"2016","journal-title":"Brain Stimulation"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1922928\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:32:57Z","timestamp":1791178377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1922928\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":56,"alternative-id":["10.3389\/fpsyt.2026.1922928"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1922928","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"1922928"}}